Pediatric Infection and Vaccine

The Korean Society of Pediatric Infectious Diseases (대한소아감염학회)
권호 표지
DOI QR코드

DOI QR Code

Influence Factors for Duration of Vancomycin Resistant Enterococci's Spontaneous Decolonization

반코마이신 저항 장구균의 자발적 집락 소실 기간에 대한 영향 인자

  • Lee, Jae Sun (Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine) ;
  • Kim, Dong Soo (Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine) ;
  • Kim, Ki Hwan (Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine)
  • 이제선 (연세대학교 의과대학 소아과학교실, 세브란스 어린이병원 소아청소년과) ;
  • 김동수 (연세대학교 의과대학 소아과학교실, 세브란스 어린이병원 소아청소년과) ;
  • 김기환 (연세대학교 의과대학 소아과학교실, 세브란스 어린이병원 소아청소년과)
  • Received : 2014.09.18
  • Accepted : 2014.10.28
  • Published : 2015.04.25
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The aim of this study was to identify the factors influencing the spontaneous decolonization period of vancomycin resistant enterococcus (VRE) species in pediatric patients. Methods: The medical records of patients presenting positive VRE cultures between January 2005 and November 2010 at a tertiary hospital in Seoul, Korea, were reviewed retrospectively. The subjects were divided into two groups according to the average number of days for decolonization (325 days). Clinical characteristics were compared between shorter VRE colonization patients (<325 days, n=41) and prolonged VRE colonization patients (>325 days, n=110). Results: There were 151 patients who had more than 1 year of follow up period or confirmed of VRE decolonization among patients who were identified with VRE. The average age at the time of initial VRE colonization was significantly younger in shorter decolonization group than in prolonged decolonization group (44.9 months vs 40.9 months, P =0.040). The prolonged decolonization group received more vancomycin treatments after VRE colonization in comparison with patients in shorter decolonization group (7.0% vs 27.2%, P =0.008). Conclusion: For the duration of VRE colonization, it was found that the initial age of acquiring VRE and use of antibiotics were important factors. Antibiotics should be used properly and precisely in order to treat infectious diseases and to control the colonization of antibiotic resistant bacteria.

목적: 소아에서 VRE의 자발적 소실 기간에 대한 영향인자들을 밝히는 것이다. 방법: 2005년 1월부터 2010년 11월까지 VRE 양성인 환자의 의무기록을 후향적으로 분석하였다. 집락소실 기간의 평균 325일을 기준으로 하여 조기소실군과 만기소실군을 나누어 임상특징을 비교하였다. 결과: VRE가 확인된 환자 중 관찰기간이 1년 이상이 되었거나 VRE 집락 소실이 확인된 수는 151명이었다. 조기소실군(41명)에서 처음 VRE 집락이 되었을 때 나이는 만기소실군(110명)에 비하여 많았다(44.9개월 vs 40.9개월, P=0.040). 그리고 조기소실군보다 만기소실군에서 VRE 집락 후 반코마이신 치료를 한 경우가 더 많았다(7% vs 27.2%, P=0.008). 결론: VRE 집락기간에 있어, 처음 VRE를 획득하였을 당시의 나이와 항생제의 사용여부가 중요하다. 감염질환을 치료하고 항생제 저항성 세균의 집락을 억제하기 위하여 적절하고 신중한 항생제 사용이 필요하다.

Keywords

References

  1. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycinresistant enterococci. Lancet 1988;1:57-8.
  2. Tenover FC, McDonald LC. Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Curr Opin Infect Dis 2005;18:300-5. https://doi.org/10.1097/01.qco.0000171923.62699.0c
  3. Burrell LJ, Grabsch EA, Padiglione AA, Grayson ML. Prevalence of colonisation with vancomycin-resistant enterococci (VRE) among haemodialysis outpatients in Victoria: implications for screening. Med J Aust 2005; 182:492.
  4. Martone WJ. Spread of vancomycin-resistant enterococci: why did it happen in the United States? Infect Control Hosp Epidemiol 1998;19:539-45. https://doi.org/10.2307/30141777
  5. Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004;24:111-8. https://doi.org/10.1016/j.ijantimicag.2003.12.019
  6. Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. Mayo Clinic proceedings. Mayo Clinic 2006;81:529-36. https://doi.org/10.4065/81.4.529
  7. Sujatha S, Praharaj I. Glycopeptide resistance in grampositive cocci: a review. Enferm Infecc Microbiol Clin 2012;2012:781679.
  8. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002;162:2223-8. https://doi.org/10.1001/archinte.162.19.2223
  9. Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, et al. Vancomycin-sensitive and vancomycinresistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Med 2002;28:692-7. https://doi.org/10.1007/s00134-002-1276-8
  10. Song X, Srinivasan A, Plaut D, Perl TM. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol 2003;24:251-6. https://doi.org/10.1086/502196
  11. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-7. https://doi.org/10.1056/NEJMoa025025
  12. Perichon B, Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009;53:4580-7. https://doi.org/10.1128/AAC.00346-09
  13. Mazuski JE. Vancomycin-resistant enterococcus: risk factors, surveillance, infections, and treatment. Surg Infect (Larchmt) 2008;9:567-71. https://doi.org/10.1089/sur.2008.9955
  14. Kauffman CA. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother 2003;51 Suppl 3:iii23-30.
  15. Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010;16:555-62. https://doi.org/10.1111/j.1469-0691.2010.03214.x
  16. Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002;62:425-41. https://doi.org/10.2165/00003495-200262030-00002
  17. Montecalvo MA. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J Antimicrob Chemother 2003;51 Suppl 3:iii31-5.
  18. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Infect Control Hosp Epidemiol 1995;23:87-94.
  19. Fisher K, Phillips C. The ecology, epidemiology and virulence of Enterococcus. Microbiology 2009;155:1749-57. https://doi.org/10.1099/mic.0.026385-0
  20. Yoon YK, Lee SE, Lee J, Kim HJ, Kim JY, Park DW, et al. Risk factors for prolonged carriage of vancomycin-resistant Enterococcus faecium among patients in intensive care units: a case-control study. J Antimicrob Chemother 2011;66:1831-8. https://doi.org/10.1093/jac/dkr204
  21. Baden LR, Thiemke W, Skolnik A, Chambers R, Strymish J, Gold HS, et al. Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of "clearance". Clin Infect Dis 2001;33:1654-60. https://doi.org/10.1086/323762
  22. Henning KJ, Delencastre H, Eagan J, Boone N, Brown A, Chung M, et al. Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 1996;15:848-54. https://doi.org/10.1097/00006454-199610000-00004
  23. Byers KE, Anglim AM, Anneski CJ, Farr BM. Duration of colonization with vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2002; 23:207-11. https://doi.org/10.1086/502036
  24. Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust 2007;186: 454-7.
  25. Szachta P, Ignys I, Cichy W. An evaluation of the ability of the probiotic strain Lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children. J Clin Gastroenterol 2011;45:872-7. https://doi.org/10.1097/MCG.0b013e318227439f
  26. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev 2010;90:859-904. https://doi.org/10.1152/physrev.00045.2009
  27. Donskey CJ, Hoyen CK, Das SM, Helfand MS, Hecker MT. Recurrence of vancomycin-resistant Enterococcus stool colonization during antibiotic therapy. Infect Control Hosp Epidemiol 2002;23:436-40. https://doi.org/10.1086/502081
  28. Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000;343:1925-32. https://doi.org/10.1056/NEJM200012283432604
  29. Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother 2002;46: 1619-28. https://doi.org/10.1128/AAC.46.6.1619-1628.2002
  30. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44:1-13.
  31. Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003;24:362-86. https://doi.org/10.1086/502213

Cited by

  1. 뇌신경질환 환자의 반코마이신 내성 장구균 집락 해제에 보중익기탕가미가 미치는 영향 : 증례 보고 vol.40, pp.5, 2019, https://doi.org/10.22246/jikm.2019.40.5.974